Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study

Figures & data

Table 1. Patient demographics and disease characteristics.

Characteristic
SS (N = 141)		n
Age (years), mean (SD)	53.3 (13.2)	141
Female, n (%)	102 (72.3)	141
Time since RA diagnosis (years), mean (SD)	6.4 (6.5)	141
Any past anti-TNF or other biologic treatment, n (%)	35 (24.8)	141
Any past anti-TNF treatment, n (%)	34 (24.1)	141
Any past biologic treatment, n (%)	7 (5.0)	141
Any prior or concomitant synthetic DMARD, n (%)	141 (100.0)	141
MTX, n (%)	137 (97.2)	141
Leflunomide, n (%)	83 (58.9)	141
Sulfasalazine, n (%)	31 (22.0)	141
Hydroxychloroquine, n (%)	3 (2.1)	141
Any other prior or concomitant medication related to RA, n (%)^a	104 (73.8)	141
FAS^b		n
DAS28(ESR)
Mean (SD)	4.8 (0.9)	80
Median (min, max)	4.8 (3.1, 6.6)	80
HAQ-DI, mean (SD)	1.5 (0.6)	95
Pain (VAS, 0–100 mm), mean (SD)	65.5 (19.4)	94
SJC, mean (SD)	6.4 (4.1)	94
TJC, mean (SD)	8.8 (6.1)	94
Fatigue (FASCA, 0–10 scale), mean (SD)	6.5 (1.9)	91

^aUsed by ≥5% of patients; ^bdata are from patients with a recording at Visit 1. DAS28(ESR): 28-joint disease activity score, calculated with erythrocyte sedimentation rate; DMARD: Disease-modifying antirheumatic drug; FASCA: fatigue assessment scale; HAQ-DI: health assessment questionnaire-disability index; MTX: methotrexate; RA: rheumatoid arthritis; SJC: swollen joint count in 28 joints; TJC: tender joint count in 28 joints; VAS: visual analogue scale.

Figure 1. Household productivity and social participation by visit (FAS) ^aDoes not include days counted in previous question (full days missed). FAS: full analysis set; LOCF: last observation carried forward.

Figure 2. Workplace productivity by visit (FAS) ^aDoes not include days counted in previous question (full days missed). FAS: full analysis set; LOCF: last observation carried forward.

Table 2. Summary of AEs to Visit 5.

	n (%) [No. of events]
Any AEs	18 (12.8) [24]
Serious AEs^a	6 (4.3) [6]
Discontinuation due to AEs	9 (6.4) [12]
Drug-related AEs	6 (4.3) [7]
Severe AEs^b	3 (2.1) [3]
Deaths	0

Data are presented for the SS (N = 141). ^aSerious AEs include those that result in death, are life-threatening, result in inpatient hospitalization (or prolongation of existing hospitalization), cause persistent or significant disability, are congenital anomalies, or are considered medically important events; ^b‘Severe’ is an indication of magnitude. AE: Adverse event.